当前位置: X-MOL 学术Trends Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Immunity beyond cancer cells: perspective from tumor tissue
Trends in Cancer ( IF 18.4 ) Pub Date : 2021-07-22 , DOI: 10.1016/j.trecan.2021.06.007
Shengyu Gao 1 , Ting-Wei Hsu 2 , Ming O Li 1
Affiliation  

Investigation of cancer as a cell-level disease has led to the development of cancer cell-directed therapies including cytotoxic T lymphocyte (CTL)-based immunotherapy; yet, many patients are refractory to these modalities of cancer treatment and acquired resistance frequently occurs. Of note, cancer environment controls the manifestation of cancerous cell phenotype. Helper T (Th) cells orchestrate immune defense responses targeting cancer cells as well as the tumor microenvironment. Recent studies have shown that in addition to interferon (IFN)-γ-producing Th1 cells, interleukin (IL)-4-producing Th2 cells function as potent anticancer effectors in part by promoting tumor stroma reconfiguration and tumor tissue repair. Such Th cell-mediated tissue-level immunity may be harnessed for novel modalities of cancer environment immunotherapy.



中文翻译:

超越癌细胞的免疫:从肿瘤组织看

将癌症作为一种细胞水平的疾病进行研究导致了癌细胞定向疗法的发展,包括基于细胞毒性 T 淋巴细胞 (CTL) 的免疫疗法;然而,许多患者对这些癌症治疗方式无效,并且经常发生获得性耐药。值得注意的是,癌症环境控制着癌细胞表型的表现。辅助 T (Th) 细胞协调针对癌细胞和肿瘤微环境的免疫防御反应。最近的研究表明,除了产生干扰素 (IFN)-γ 的 Th1 细胞外,产生白介素 (IL)-4 的 Th2 细胞还可以通过促进肿瘤基质重构和肿瘤组织修复来发挥有效的抗癌效应。这种 Th 细胞介导的组织水平免疫可用于癌症环境免疫治疗的新模式。

更新日期:2021-07-22
down
wechat
bug